开发KRAS双重抑制剂!与艾伯维“牵手”7个月后,B轮达8850万美元( 二 )


参考资料:
1#FrontierMedicinesRaises$88.5MillionSeriesBFinancingtoAdvancePrecisionOncologyandTargetedProteinDegradationPipeline.(来源:FrontierMedicines)
2#FrontierMedicinesandAbbVieEstablishGlobalPartnershiptoDiscoverandDevelopNovelTherapiesandE3DegradersAgainstDifficult-to-DrugTargets(来源:FrontierMedicines)